作者: Gary R. Morrow , Jane T. Hickok , Joseph A. Roscoe , Richard F. Raubertas , Paul L.R. Andrews
关键词: Internal medicine 、 Depression (differential diagnoses) 、 Antidepressant 、 Serotonin reuptake inhibitor 、 Clinical trial 、 Anesthesia 、 Medicine 、 Placebo 、 Randomized controlled trial 、 Paroxetine 、 Paroxetine Hydrochloride
摘要: Purpose: Fatigue and depression typically occur together in cancer patients, suggesting a common etiology, perhaps based on serotonin. This randomized clinical trial tested whether paroxetine, selective serotonin reuptake inhibitor antidepressant known to modulate brain serotonin, would reduce fatigue patients any reduction was related depression. Patients Methods: Cancer undergoing chemotherapy for the first time were assessed fatigue. Of 704 who reported at their second cycle, 549 randomly assigned receive either 20 mg of oral paroxetine hydrochloride daily or placebo 8 weeks. The assessments performed cycles 3 4 chemotherapy. Results: A total 244 treated with 235 provided assessable data. No difference detected between patient groups. At end study, there groups i...